Ondansetron formulations

Ondansetron is also available in an oral formulation, which can be used for mildly or moderately emetogenic chemotherapy. In one double-blind trial in 318 patients taking combinations of cyclophosphamide with methotrexate and/or doxorubicin, oral ondansetron 1, 4, or 8 mg t.i.d. for 3 d was completely effective in preventing emesis in 57,65, and 66% of patients, respectively, compared to 19% who did not vomit with placebo. 

Pluronic lecithin organogels have been tested for the topical delivery of ondansetron (5-HT3 receptor antagonist). The formulations exhibited dose-dependent attenuation of nociceptive and... 

Other microspheres for nasal adsorption were formulated with amlodipine, a long-acting dihydropyridine-type (DHP) calcium channel blocker used to lower blood pressure [104] and ondansetron, used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery [105]. 

Ondansetron has been described as the free base, hydrochloride salt and hydrochloride dihydrate and is available in a variety of formulations. These include hydrochloride tablets (4 and 8 mg) and solutions for injection (2 mg/ mL), oral lyophilisates (4 and 8 mg), sugar-free syrup (4 mg/5 mL as hydrochloride) and suppositories (16 mg). Alosetron hydrochloride tablets (0.5 and 1 mg) are most commonly obtainable. Tropisetron is also available as the hydrochloride salt and comes either as capsules (5 mg) or as a solution for injection at 1 mg/mL. Dolasetron mesilate products are formulated as film-coated tablets (50 and 200 mg) and 20 mg/mL solution for injection. Granisetron is also available as the hydrochloride salt and appears as film-coated tablets (1 and 2 mg) and 1 mg/mL solution for injection and dilution. 

---